US5162374A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for reversibly arresting muscle activity
Assignee: University of Vermont
•
Filing: 1991-06-12
•
Granted: 1992-11-10
•
Expires: 2011-06-12
Abstract
Abstract Muscle activity can be reversibly arrested by administering a reagent, such as 2,3-butanedione monoxime (BDM), which selectively blocks the interaction of the contractile proteins actin and myosin. Muscle such as the heart is contacted with the reagent to arrest activity and, after surgery or transplantation, the reagent is removed from the muscle to restore muscle activity. The preferred reagent BDM has the following structure: ##STR1##
Inventors
- 👤 Louis A. Mulieri
- 👤 Gerd Hasenfuss
- 👤 Norman R. Alpert
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 23:24
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/15; A01; A01N; A01N1/00; A01N1/10; A01N1/12; A01N1/122; A01N1/126; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/28
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
79 words
A method for reversibly arresting human cardiac muscle activity comprising the steps of: a. contacting cardiac muscle tissue with an effective amount of a diffusible, non-toxic chemical agent which selectively and reversibly blocks the interaction of the contractile proteins actin and myosin thereby eliminating contraction and its associated consumption of energy; and b. following a selected amount of time, removing an amount of the chemical agent form contact with the cardiac muscle tissue sufficient to restore the muscle activity.
Claim 2
Independent Claim
79 words
A method for reversibly arresting human cardiac muscle activity comprising the steps of: a. contacting cardiac muscle tissue with an effective amount of a diffusible, non-toxic chemical agent which selectively and reversibly blocks the interaction of the contractile proteins actin and myosin thereby eliminating contraction and its associated consumption of energy; and b. following a selected amount of time, removing an amount of the chemical agent form contact with the cardiac muscle tissue sufficient to restore the muscle activity.
Claim 3
Dependent Claim
15 words
The method of claim 1, wherein the chemical agent is 2,3-Butanedione monoxime or homologues thereof.
Claim 4
Independent Claim
58 words
A method of reversible cardioplegia for heart transplantation, comprising the steps of: a. contacting a human donor heart with an effective cardioplegic amount of 2,3-Butanedione monoxime; b. maintaining the heart in contact with the 2,3-Butanedione monoxime; and c. surgically introducing the heart into a recipient patient and removing the 2,3-Butanedione monoxime from the heart to reverse the cardioplegia.
Claim 5
Independent Claim
58 words
A method of reversible cardioplegia for heart transplantation, comprising the steps of: a. contacting a human donor heart with an effective cardioplegic amount of 2,3-Butanedione monoxime; b. maintaining the heart in contact with the 2,3-Butanedione monoxime; and c. surgically introducing the heart into a recipient patient and removing the 2,3-Butanedione monoxime from the heart to reverse the cardioplegia.
Claim 6
Dependent Claim
18 words
The method of claim 3, wherein the 2,3-butanedione monoxime is introduced into coronary circulation to induce the cardioplegia.
Claim 7
Dependent Claim
27 words
A method of claim 3, wherein the myocardium is immersed into a physiologically acceptable solution comprising an effective cardioplegic amount of 2,3-butanedione monoxime or a homologue thereof.
Claim 8
Dependent Claim
13 words
The method of claim 3, wherein 2,3-butanedione is in a physiologically acceptable solution.
Claim 9
Dependent Claim
36 words
A method of claim 6, wherein the solution comprises Na + , K + , Cl - , HCO 3 - , Mg 2+ , H 2 PO 4- SO 4 2- Ca 2+ and glucose.
Claim 10
Dependent Claim
19 words
A method of claim 3, further comprising reversing the cardioplegia by removing the 2,3-butanedione from contact with the myocardium.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-11-10 | 1996-05-11 | 1996-11-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-11-10 | 2000-05-11 | 2000-11-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-11-10 | 2004-05-11 | 2004-11-10 | $7700.00 | Window Closed / Lapsed |